Accumulate Testnet 8.0 Millennium – Mainnet Release Candidate 2
Accumulate developers are announcing Testnet 8 Millennium – Mainnet Release Candidate 2. Named after the Millennium bridge located in London, England, Accumulate’s Testnet 8.0 includes a variety of updates.
Additionally, from this point onwards (until further notice), there will be two Testnets to make sure that third-party applications can remain stable. In addition, the DevNet will remain. The mobile application is compatible with the Beta RC1 version of the Testnet.
- Testnet Beta RC1 is Testnet 7.0
- Testnet Beta RC2 is Testnet 8.0
- DevNet is DevNet
The mobile application will point to the Testnet Beta RC1 is Testnet 7.0 endpoint, which will be compatible with the Testnet Beta RC1 branch (Develop Branch – tag cli-v1.0.0-rc1.2) in the CLI and Testnet Beta RC1 in the Explorer (https://beta.explorer.accumulatenetwork.io/). To use new features in Accumulate, connect to the Testnet Beta (8.0) Branch (Develop Branch – Tag cli-v1.0.0-rc2) in the CLI and use the Testnet Beta RC2 option in the Explorer (https://explorer.accumulatenetwork.io/). To interact with the Devnet use the Develop branch in the CLI and the Devnet option in the explorer (https://dev.explorer.accumulatenetwork.io/).
To switch from one branch to another in the CLI type git branch and the branch you would like to connect to. Make sure to do a git pull and go build to get the latest updates in the CLI.
Protocol Highlights
- Integrate Factom snapshot with Accumulate Genesis Tool – this will allow Accumulate to take a snapshot of Factom at a particular block height and import data into the Accumulate Genesis Block
- Allow new Factom data entries – a user can choose to write data in the same manner as a Factom data entry
- Variable fee schedule update – for multi-operation commands in Accumulate, such as sending ACME tokens to multiple outputs, each additional output will be charged a fee. Please see the change in the fee schedule below:
https://docs.accumulatenetwork.io/accumulate/getting-started/fees
Alpine 4 Holdings Announces That It Has Been Approved to List on The Nasdaq
PHOENIX, Oct. 14, 2021 /PRNewswire/ — Alpine 4 Holdings, Inc., a Delaware Corporation (Symbol: ALPP), (the “Company”), announced today that it has been approved by The Nasdaq Stock Market to list on The Nasdaq Capital Market effective at the open of the market on Wednesday, October 20, 2021, under the trading symbol ALPP.
Kent Wilson, CEO, had this to say about the Nasdaq approval: “This has been a long-anticipated event, and I can state enthusiastically that we are very pleased to be joining Nasdaq. I want to say thank you to all our hard-working employees and shareholders who helped make this day possible!”
In conjunction with the Nasdaq listing, the Company has also promoted Larry Zic from Chief Accounting Officer to Chief Financial Officer and has appointed Mike Loyd to the Board of Directors and to become Chair of the Audit Committee.
Mr. Zic has been with the Company since April 2020, originally serving as Corporate Controller. Later, he became the Company’s Chief Accounting Officer. Mr. Zic has a Bachelor of Accounting degree from St. Joseph’s College in Indiana, and a Master of Business Administration degree from Indiana University Bloomington.
Mr. Loyd currently serves as the Treasurer and SVP at Old National Bank in Fort Branch, Indiana. Mr. Loyd has a Bachelor of Business Administration degree from the University of Kentucky and a Master of Business Administration degree from Auburn University.
About Alpine 4 Holdings: Alpine 4 Holdings, Inc. (ALPP), is a publicly traded conglomerate that acquires businesses that fit into its disruptive DSF business model of Drivers, Stabilizers, and Facilitators. Alpine 4 understands the nature of how technology and innovation can accentuate a business. Alpine 4 focuses on how the adaptation of new technologies, even in brick-and-mortar businesses, can drive innovation. Alpine 4 also believes that its holdings should benefit synergistically from each other, have the ability to have collaborate across varying industries, spawn new ideas, and create fertile ground for competitive advantages.
Four principles at the core of Alpine 4’s business are Synergy. Innovation. Drive. Excellence. Alpine 4 believes synergistic innovation drives excellence. By anchoring these words to the Company’s combined experience and capabilities, Alpine 4 can aggressively pursue opportunities within and across vertical markets. Alpine 4 delivers solutions that not only drive industry standards, but also increase value for the Company’s shareholders.
Forward-Looking Statements: The information disclosed in this press release is made as of the date hereof and reflects Alpine 4’s most current assessment of its historical financial performance. Actual financial results may differ from those contained herein due to timing delays between the date of this release and confirmation of final audit results. Any forward-looking statements in this press release are not guarantees of future performance and are subject to uncertainties and other factors that could cause actual results to differ materially from those expressed in the forward-looking statements including, without limitation, the risks, uncertainties, including the uncertainties surrounding the current market volatility, and other factors the Company identifies from time to time in its filings with the SEC. Although Alpine 4 believes that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate and, as a result, the forward-looking statements based on those assumptions also could be incorrect. You should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this release are made as of the date hereof, and Alpine 4 disclaims any intention or obligation to update the forward-looking statements for subsequent events.
Stem Cell Therapy for the Coronavirus COVID-19 Pandemic
March 17, 2020 – Vitro Diagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma reports on its therapy for the Coronavirus (COVID-19) pandemic.
Recent umbilical cord stem cell therapies in China to fight the Coronavirus are producing encouraging emergency results. Vitro Biopharma has the highest level of umbilical cord stem cell technology to reduce death rates due to the Coronavirus pandemic.
https://www.scmp.com/news/china/society/article/3053080/coronavirus-critically-ill-chinese- patient-saved-stem-cell
https://www.dailytargum.com/article/2020/03/commentary-compassionate-use-of-stem-cell- therapy-to-treat-severe-covid-19-could-save-lives-now
http://www.aginganddisease.org/article/0000/2152-5250/ad-0-0-216.shtml
Dr. Jim Musick, Ph.D., CEO said, “As the world struggles to deal with the COVID-19 pandemic, it is important to consider stem cell therapy to reduce death rates. This is supported by clinical studies and clinical trials are underway to substantiate safety and efficacy. Vitro Biopharma is ideally suited to provide high quality stem cells to US patients, produced under strict quality control in a cGMP, ISO9001 & ISO13485 Certified environment. Our umbilical cord AlloRx™ Stem Cells and stem cell growth media MSC-Gro™ have been used in the treatment of hundreds of patients without adverse events and show efficacy in treatment of COPD, osteoarthritis, multiple sclerosis and Alzheimer’s disease.
Out of years of research, we developed our patent-pending and proprietary line of umbilical cord derived stem cells AlloRx™ Stem Cells now being used in offshore regenerative medicine clinical trials. Our stem cells are used in regenerative medicine clinical trials with our partner in the Cayman Islands www.DVCStem.com.
Vitro Biopharma has a patent-pending, proprietary and scalable manufacturing platform to provide stem cell therapies to critically ill Coronavirus patients. Our stem cells have been shown to be safe in Phase I protocols as we also gain evidence of efficacy.
We are in contact with federal, state and local governments to inform them of our AlloRx ™ Stem Cell therapy option for Coronavirus infections.. The pandemic deserves consideration of all therapeutic options and there is evidence that stem cell therapy reduces the death rate from Coronavirus COVID-19 infections. We believe that critically ill patients should have the right to try stem cell therapy in the United States.”
CONTACT:
Dr. James Musick Chief Executive Officer
Vitro Biopharma (303) 550-2778
E-mail: jim@vitrobiopharma.com
Source: Vitro Diagnostics, Inc
Forward-Looking Statements
Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company’s auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain “forward-looking statements”. Such forward looking statements are identified by words such as “intends,”
“anticipates,” “believes,” “expects” and “hopes” and include, without limitation, statements regarding the Company’s plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.
Factors that could cause actual results to differ materially include, among others, acceptability of the Company’s products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company’s filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements.
Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.
Lethean (IntenseCoin) Explained: The Decentralized VPN Cryptocurrency Project
by Jacob Woods
What is Lethean
Lethean, incorporated in the UK, has created a decentralized VPN marketplace. Lethean has been described as the “first Mainnet P2P Virtual Private Network backed by the Blockchain.”
Users can take advantage of the browser extension or the full client VPN. Anyone can mine the coin or operate an exit node to earn LTHN. LTHN is used as payment for the VPN services. This VPN marketplace allows you to select a specific country, price, and speed.
LTHN is a proof-of-work coin based on CryptoNote. Monero is another example of a CryptoNote coin. Lethean, like XMR, uses ring signatures and one-time keys to make transactions unlinkable and untraceable. LTHN uses the CryptoNightR hashing algorithm. LTHN implemented CryptoNightR 10 hours before Monero did.
Introducing Facebook Cryptocurrency Libra
Welcome to Libra. Libra is a global, digitally native, reserve-backed cryptocurrency built on the foundation of blockchain technology. People will be able to send, receive, spend, and secure their money, enabling a more inclusive global financial system.
Our mission is to enable a simple global currency and financial infrastructure that empowers billions of people, and our hope is to create more access to better, cheaper, and open financial services — no matter who you are, where you live, what you do, or how much you have. Find out more at Libra.org. Read the Libra White Paper.
More about Libra from The Verge
Also see “Libra: Cryptocurrency By Facebook (In 5 Minutes)” from MrBTC.org
